Eli Lilly and Company $LLY is Rowlandmiller & PARTNERS.ADV’s 8th Largest Position

Rowlandmiller & PARTNERS.ADV trimmed its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 8.8% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 17,397 shares of the company’s stock after selling 1,674 shares during the quarter. Eli Lilly and Company accounts for about 2.6% of Rowlandmiller & PARTNERS.ADV’s investment portfolio, making the stock its 8th biggest position. Rowlandmiller & PARTNERS.ADV’s holdings in Eli Lilly and Company were worth $13,274,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Wealth Preservation Advisors LLC acquired a new stake in Eli Lilly and Company during the 1st quarter valued at approximately $27,000. Sumitomo Mitsui Financial Group Inc. purchased a new position in shares of Eli Lilly and Company during the 2nd quarter valued at approximately $27,000. Evolution Wealth Management Inc. purchased a new position in shares of Eli Lilly and Company during the 2nd quarter valued at approximately $29,000. Financial Gravity Companies Inc. acquired a new stake in shares of Eli Lilly and Company during the second quarter worth approximately $31,000. Finally, Bare Financial Services Inc increased its stake in shares of Eli Lilly and Company by 263.6% in the second quarter. Bare Financial Services Inc now owns 40 shares of the company’s stock worth $31,000 after buying an additional 29 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have commented on LLY shares. Leerink Partnrs upgraded shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Monday, November 10th. JPMorgan Chase & Co. increased their price target on shares of Eli Lilly and Company from $1,050.00 to $1,150.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 18th. Sanford C. Bernstein boosted their price objective on Eli Lilly and Company from $1,100.00 to $1,300.00 and gave the company an “outperform” rating in a report on Monday, November 24th. Guggenheim restated a “buy” rating and set a $1,163.00 price objective on shares of Eli Lilly and Company in a research note on Wednesday, December 3rd. Finally, Weiss Ratings reiterated a “buy (b-)” rating on shares of Eli Lilly and Company in a report on Tuesday, December 9th. Three analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $1,128.55.

Eli Lilly and Company Stock Performance

Shares of LLY stock opened at $1,062.67 on Tuesday. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,111.99. The company has a debt-to-equity ratio of 1.71, a current ratio of 1.55 and a quick ratio of 1.24. The firm has a market capitalization of $1.00 trillion, a price-to-earnings ratio of 51.99, a price-to-earnings-growth ratio of 1.14 and a beta of 0.37. The business has a 50 day simple moving average of $943.82 and a 200 day simple moving average of $822.76.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.42 by $0.60. The company had revenue of $17.60 billion during the quarter, compared to analyst estimates of $16.09 billion. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The firm’s quarterly revenue was up 53.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, equities research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be issued a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 0.7%. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date is Friday, February 13th. Eli Lilly and Company’s payout ratio is 29.35%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.